We advised the initial purchasers on the offering

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A offering by NeoGenomics, Inc. of $316.25 million aggregate principal amount of its 0.75% convertible senior notes due 2032, including $41.25 million aggregate principal amount of convertible notes pursuant to the exercise in full of the initial purchasers’ option to purchase additional convertible notes. In addition, Davis Polk advised the counterparties to the capped call transactions entered into in connection with the offering.

NeoGenomics is a premier cancer diagnostics company specializing in cancer genetics testing and information services. The company offers one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, Florida, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the United States and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Julia Molo and Grace Yongxi Pan. The equity derivatives team included partner Mark M. Mendez and associates Alexander S. Pettingell and Zifeng Zeng. The intellectual property team included partner David R. Bauer and associate Ryan Grawe. The tax team included partner Aliza Slansky. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post